Instrument Inactif

Communiqués ARRD RESE Nasdaq

Actions

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

30/07	ARROWHEAD PHARMACEUTICALS, INC. : B. Riley toujours positif	ZM
29/07	ARROWHEAD PHARMACEUTICALS, INC. : RBC Capital Markets reste à l'achat	ZM

Communiqués

27/07	Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	BU
22/07	Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia	BU
21/07	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results	BU
23/06	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome	AQ
22/06	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)	BU
18/06	Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars	BU
02/06	Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events	BU
27/05	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026	BU
26/05	Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress	BU
14/05	Arrowhead Pharmaceuticals : ECO 2026 LBP4078 Kerr Activin E Poster 6May2026 FINAL	PU
13/05	Arrowhead Pharmaceuticals : TIDES 2026 KM final (1)	PU
08/05	Arrowhead Pharmaceuticals : ARWR FQ2 2026 Script FINAL	PU
07/05	Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results	BU
05/05	Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals	BU
04/05	Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events	BU
01/05	Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)	BU
27/04	Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe	AQ
24/04	Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe	BU
20/04	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results	BU
30/03	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo	AQ
28/03	Arrowhead Pharmaceuticals : ACC 2026 1006 03 SHASTA MUIR OLE 24Mar2026	PU
28/03	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo	BU
24/02	Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events	BU
05/02	Arrowhead Pharmaceuticals : ARWR FQ1 2026 Script Final	PU
05/02	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results	BU